Up to €37.5m of Median’s funding comes from the EIB, and €10m from an equity line with IRIS Capital Investment.
The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, reaching ...
Coauthor by Hindsight, a developer-focused compliance software platform for medical device creation, has launched a new ...
After the rejection of Hutchmed’s treatment, despite the efforts to include a bridging trial, the FDA seems to have drawn a line in the sand, effectively requiring multiregional clinical trials ...
The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ 0.91 ...
An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...
The FDA rejected the company’s initial NDA in 2021, citing the lack of an adequate trial to demonstrate efficacy.
Currently, the drug's FDA-approved loading regimen features three ... This time around, NICE assessed the med using a faster cost comparison process that compared Lynparza to Pfizer’s Talzenna ...
This is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.
You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.